Deep Brain Reorienting in Post-traumatic Stress Disorder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04317820 |
Recruitment Status :
Recruiting
First Posted : March 23, 2020
Last Update Posted : October 21, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
PTSD Post-traumatic Stress Disorder | Behavioral: Deep Brain Reorienting (DBR) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 124 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Participants will be randomized to either the DBR treatment or wait-list conditions. |
Masking: | Single (Outcomes Assessor) |
Masking Description: | Only the outcome assessors will be blinded to which condition the participant was assigned. |
Primary Purpose: | Treatment |
Official Title: | The Effects of Deep Brain Reorienting (DBR) on Post-traumatic Stress Disorder (PTSD) |
Actual Study Start Date : | September 29, 2020 |
Estimated Primary Completion Date : | September 2023 |
Estimated Study Completion Date : | September 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: DBR Condition
Involves 8 weekly sessions of DBR treatment.
|
Behavioral: Deep Brain Reorienting (DBR)
Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm. |
No Intervention: Wait-list Condition
No intervention for approximately 8 weeks.
|
- change in PTSD symptoms from baseline as measured by the Clinician Administered PTSD Scale (CAPS) at post-treatment assessment [ Time Frame: 8 weeks ]min. CAPS score=0, max=80, with higher scores representing greater PTSD symptoms
- change in PTSD symptoms from post-treatment assessment as measured by the Clinician Administered PTSD Scale (CAPS) at follow-up assessment [ Time Frame: 3 months ]min. CAPS score=0, max=80, with higher scores representing greater PTSD symptoms

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- English speaking
- age: 18-65
- meets diagnostic criteria for PTSD (as determined by study assessment)
- may benefit from short-term trauma therapy (as determined by study assessment)
Exclusion Criteria:
- Individuals with any implants, conditions, etc. that do not comply with 7-Tesla (7T) fMRI research safety standards (e.g., certain implants, pregnancy)
- history of significant head injury/lengthy loss of consciousness (e.g., a Glasgow Coma Scale Score < 15 at the time of incident assessed retrospectively by participant)
- significant untreated medical illness
- history of neurological disorder
- history of any pervasive developmental disorder
- history of bipolar disorder
- history of psychotic disorder
- alcohol/substance abuse or dependence within the last 3 months
- extensive narcotic use
- current participation in counselling more extensive than supportive therapy (e.g., exposure therapy, Cognitive-Behavioural Therapy would be an exclusion)
- a degree of mental distress that is unlikely to benefit from a short-term therapy (for our participants' well-being, it will be necessary that we believe it possible to safely address the issues/triggers brought up in treatment within the 8 sessions).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04317820
Contact: Suzy - Study Coordinator | 519-685-8500 ext 35186 | Suzy.Southwell@lhsc.on.ca |
Canada, Ontario | |
London Health Sciences Centre - University Hospital | Recruiting |
London, Ontario, Canada, N6A 5A5 | |
Contact: Suzy -Study Coordinator 519-685-8500 ext 35186 suzy.southwell@lhsc.on.ca |
Principal Investigator: | Ruth A Lanius, MD, PhD | Lawson Health Research Institute |
Responsible Party: | Ruth Lanius, Principal Investigator, Lawson Health Research Institute |
ClinicalTrials.gov Identifier: | NCT04317820 |
Other Study ID Numbers: |
8997 114501 ( Other Identifier: Western University's Human Research Ethics ) |
First Posted: | March 23, 2020 Key Record Dates |
Last Update Posted: | October 21, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Deep Brain Reorienting DBR |
Stress Disorders, Traumatic Stress Disorders, Post-Traumatic Trauma and Stressor Related Disorders Mental Disorders |